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Implication for health policy/practice/research/medical education: {#key1}
==================================================================

Rituximab is currently approved by the US Food and Drug Administration (FDA) for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. In addition, rituximab has recently been used as an off-label treatment in a number of diseases. However, its detailed cardiotoxicity profile and effects on cardiac function are not clearly described in the literature. This case of non-ischemic cardiomyopathy after infusion of rituximab for membranous nephropathy highlights the growing evidence that rituximab can affect cardiac function and requires greater attention as a causative agent of cardiomyopathy.

Introduction {#s1}
============

Rituximab, a chimeric monoclonal anti-CD20 antibody, is currently approved by the US Food and Drug Administration (FDA) for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) ([@R1]-[@R5]). In addition to these indications, the use of rituximab has been expanded as an off-label treatment for many diseases including systemic lupus erythematosus, Sjögren's syndrome, idiopathic thrombocytopenic purpura, bullous dermatologic diseases, membranous nephropathy, steroid-dependent or frequently relapsing idiopathic nephrotic syndrome, treatment in recurrent and de novo glomerular disease after renal transplantation, and others ([@R6]-[@R9]).

Despite its relative safety profile, infusion-related side effects of rituximab, such as fevers, chills and rigors are common, reported to be as high as 87% ([@R2]-[@R5],[@R10],[@R11]). Due to reported cases of angina, acute coronary syndrome (ACS), and arrhythmias related to rituximab infusion, caution for its use is advised by FDA in patients with a history of cardiovascular disease ([@R12]). However, its detailed cardiotoxicity profile and effects on cardiac function are not clearly described in the medical literature. We report a case of a 51-year-old man who developed non-ischemic cardiomyopathy after receiving his first infusion of rituximab for membranous nephropathy. This case highlights the growing evidence that rituximab can affect cardiac function and requires greater attention as a potential causative agent of cardiomyopathy.

Case Presentation {#s2}
=================

A 51-year-old man was diagnosed with phospholipase A2 receptor (PLA2R) positive, primary membranous nephropathy. He was initially treated with prednisone and cyclophosphamide without significant improvement. The patient was subsequently started on tacrolimus and became calcineurin inhibitor-dependent. Due to a relapse despite being on tacrolimus, rituximab treatment was recommended. His past medical history was remarkable for multiple episodes of deep venous thrombosis on chronic anticoagulation, hypertension, and dyslipidemia. He did not have any previous cardiac history and denied any concerning preceding cardiac symptoms of chest pain, dyspnea, syncope, orthopnea, or paroxysmal nocturnal dyspnea. The patient had a 33-pack-year history of smoking but quit two years previously. His 12-lead electrocardiogram (ECG) prior to rituximab treatment showed normal sinus rhythm. He worked as a carpenter and had been carrying heavy equipment at work without significant physical limitation. His family history is significant for coronary artery disease in his father at 50 years of age and dilated cardiomyopathy (DCM) in his brother. Due to significant cardiovascular diseases in his family members the patient underwent a cardiolite treadmill stress test which showed normal exercise tolerance and functional class I on Bruce protocol for 15 minutes. There was no evidence of fixed or reversible defect.

The patient was 179 cm tall with a body weight of 88 kg and body surface area (BSA) of 2.1 m^2^. Rituximab was administered at a dosage of 1000 mg intravenous (IV) at a starting infusion rate of 50 mL/h. Oral acetaminophen (1000 mg), oral diphenhydramine (50 mg), and IV methylprednisolone (100 mg) were also given as premedication. He underwent his first rituximab infusion without any immediate side effects. Forty-eight hours after the infusion, the patient presented to the hospital and reported having woken up from sleep with chest tightness and shortness of breath. He also had nausea and emesis. His physical examination was unremarkable with no evidence of heart failure.

A 12-lead ECG showed a new left bundle branch block (LBBB) as shown in [Figure 1](#F1){ref-type="fig"}. Troponin I level was 0.08 ng/mL (normal \<0.03 ng/mL). Otherwise, Laboratory testing revealed the following values: hemoglobin 11.2 g/dL (reference range 13.5-17.5 g/dL), white blood cell count 9.6×10^9^/L (reference range 3.5-10.5 ×10^9^/L), platelet 157×10^9^/L (reference range 150-450 ×10^9^/L), serum creatinine 1.5 mg/dL (reference range 0.8-1.3 mg/dL), BUN 41 mg/dL (reference range 8-24 mg/dL), sodium 141 mmol/L (reference range 135-145 mmol/L), potassium 5.0 mmol/L (reference range 3.6-5.2 mmol/L), chloride 111 mmol/L (reference range 100-108 mmol/L), bicarbonate 22 mmol/L (reference range 22-29 mmol/L). Computed tomography angiogram of the chest was negative for pulmonary embolism without evidence of significant coronary calcification. An urgent transthoracic echocardiogram demonstrated moderately reduced left ventricular (LV) systolic function with an ejection fraction (EF) of 30% with moderate hypokinesis of the anteroseptal myocardium. There was no significant valvular disease. The patient subsequently underwent left and right heart catheterization with coronary angiography which revealed a cardiac output of 5.9 L/min (normal range: 4-8L/min) and a cardiac index of 2.88 L/min/m^2^(normal range: 2.6--4.2 L/min/m^2^). There was no significant atherosclerotic disease noted in the coronary vessels. However, there was moderate diffuse hypokinesis of the LV on ventriculogram. Right heart catheterization demonstrated mildly elevated right and left-sided filling pressures. Thus, the diagnosis of non-ischemic cardiomyopathy was made, and the underlying etiology of his non-ischemic cardiomyopathy was postulated to be due to rituximab treatment.

![](jrip-6-18-g001){#F1}

The patient received medical treatment for the cardiomyopathy with carvedilol 3.125 mg orally twice a day as well as lisinopril 10 mg and rosuvastatin 10 mg orally once a day. The patient was also subsequently placed on a life vest due to prevent sudden cardiac death. The patient was restarted on tacrolimus for his treatment of membranous nephropathy. He did not receive any further treatment with rituximab. A repeat echocardiogram one month later still demonstrated severe LV enlargement with a calculated EF of 26%. There was persistent generalized LV hypokinesis with abnormal ventricular septal wall motion due to LBBB. Otherwise, there was a mild valvular heart disease. His follow-up ECG showed normal sinus rhythm with LBBB. Carvedilol was increased to 6.25 mg twice a day and slowly titrated up to 25 mg twice a day. At 9-month follow-up, despite that he had better optimization of his medical therapy, his transthoracic echocardiogram still showed reduced LVEF of 31% with moderate−severe LV enlargement. Thus, the patient was evaluated and underwent cardiac resynchronization therapy with implantable cardioverter defibrillators (CRT-D) implantation. At 3 month after initiation of CRT therapy, the patient had significant improvement in his functional status with LVEF of 52%. Although the patient still had proteinuria at 607 mg/dL/24 hours, his kidney function remained stable with creatinine of 1.6 mg/dL and creatinine clearance of 69 mL/min/BSA.

Discussion {#s3}
==========

Rituximab, B-cell-depleting agent targeting CD20 antigen, is being increasingly and effectively used "off label" for various conditions including glomerular diseases such as lupus nephritis, membranous nephropathy, focal segmental glomerulosclerosis, cryoglobulinemic glomerulonephritis, antibody-mediated renal allograft rejection and recurrent glomerulonephritis in renal allograft ([@R6]-[@R9],[@R13]). However, the data regarding its cardiac side effect profile are not well recognized. We report a rare, but serious cardiac adverse effect of irreversible/partial reversible non-ischemic cardiomyopathy following rituximab treatment in a patient with membranous nephropathy.

To identify potential previously reported cases of potential cardiovascular adverse effects related to rituximab treatment, the literature searches of Embase, Medline and Cochrane through July 2016 was performed using the terms "rituximab" and "rituxan" combined with the terms "cardiac", "cardiovascular", "cardiomyopathy", "coronary" and "heart". Not surprisingly, some reports have stated that rituximab is safe for the heart ([@R2]-[@R5]). This finding is also consistent with the data from our recent published data from a multicenter, randomized, double-blind controlled trial comparing the efficacy of rituximab with conventional immunosuppression with cyclophosphamide for the treatment of severe ANCA--associated vasculitis in 197 patients ([@R1]). There was no significant difference in serious or non--disease-related adverse event between two groups. Also, significant or serious cardiovascular adverse effects were not noted.

Rituximab is well known to cause infusion-related side effects from cytokine release, such as fevers and rigors within the ﬁrst few hours, especially during the ﬁrst infusion. These symptoms are associated with cytokine release, particularly interleukin 6 (IL-6). Most of these cases resolve promptly with supportive management. Hypotension, angioedema, hypoxia, and bronchospasm can also be seen in up to 10% of cases ([@R10],[@R11]). With previously reported cases of angina, ACS, and arrhythmias with rituximab infusion ([@R14]-[@R25]), FDA has cautiously provided recommendations to discontinue infusions for serious or life-threatening cardiac arrhythmias and perform cardiac monitoring during and after all infusions of rituximab for patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina ([@R12]). However, these current recommendations do not sufficiently address the cardiovascular concerns related to rituximab treatment, since cases with adverse cardiovascular effects following rituximab infusion have been additionally reported as shown in [Table 1](#T1){ref-type="table"}. In addition to ACS and arrhythmia, rituximab-induced cardiogenic shock, delayed reduction in LVEF, Takotsubo's and non-ischemic cardiomyopathies have also been described ([@R14]-[@R23],[@R25],[@R26]) as summarized in [Table 2](#T2){ref-type="table"}.

###### Reported cases with cardiovascular adverse effect following rituximab infusion

  -------------------------------- ---------- ------------------ ----------------------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------ ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                   **Year**   **No. of cases**   **Demographics**                                                                    **Indication for Rituximab treatment**                          **Cardiovascular toxicities**              **Onset**                                                           **Prior cardiac history**                                                                                                                          **Electrocardiogram (Post infusion)**                                                                    **Echocardiogram**                                                                                                                                                    **Coronary angiography**                                                                                                                        **Outcomes**

  Garypidou et al‏([@R14])         ‏2004      1                  A 71-year-old male                                                                  Non-Hodgkin lymphomas and B-cell chronic lymphocytic leukemia   Unstable angina/acute coro-nary syndrome   Four hours after the initiation of the ﬁrst infusion                Myocardial infarction 12 years previously                                                                                                          Sinus tachycardia with no ST-segment or T-wave changes                                                   NR                                                                                                                                                                    NR                                                                                                                                              The pain resolved with the administration of nitroglycerin sublingually and the infusion was interrupted. During the next few days, there was no elevation of the biochemical cardiac markers or ECG changes.

  Millward et al‏([@R15])          ‏2005      1                  A 20-year-old female                                                                Refractory thrombotic thrombocytopenia purpura                  Cardiogenic shock                          Six hours after the rituximab infusion                              None                                                                                                                                               NR                                                                                                       Acute biventricular cardiogenic shock with EF of 5%-10%                                                                                                               NR                                                                                                                                              1 week after cardiogenic shock, biventricular systolic and diastolic functions were normalized.

  Kanamori et al ([@R16])          ‏2006      3                  A 80-year-old man, 65-year-old man, and 55 year-old man                             Non-Hodgkin's lymphoma                                          Delayed reduction in LV function           -Case 1: 2 weeks after rituxi-mab\                                  -Case 1: no risk factor for cor-onary artery disease\                                                                                              NR                                                                                                       -Case 1: EF 35% 2 weeks after rituximab\                                                                                                                              NR                                                                                                                                              -Case 1: died\
                                                                                                                                                                                                                                                                -Case 2: after the sixth course\                                    -Case 2: smoking\                                                                                                                                                                                                                                           -Case 2: EF decreased to 50% after the sixth course from 65% before treatment\                                                                                                                                                                                                                                        -Case 2: asymptomatic\
                                                                                                                                                                                                                                                                -Case 3: after the fourth course                                    -Case 3: smoking                                                                                                                                                                                                                                            -Case 3: EF decreased to 55% after the fourth course from 73% before treatment                                                                                                                                                                                                                                        -Case 3: recovered one month after treatment

  Armitage et al ([@R17])\         ‏2008      3                  The median age of 61 years                                                          Lymphoproliferative disorders                                   Acute coronary syndromes                   Initial infusion of rituximab                                       One patient had known athero-sclerotic heart disease, and 2 patients had risk factors for coronary artery disease                                  NR                                                                                                       NR                                                                                                                                                                    NR                                                                                                                                              One patient died of an ar-rhythmia that deteriorated into asystole, and 2 patients recov-ered and underwent coronary angiography
  \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Poterucha et al ([@R18])         ‏2010      ‏1                 A 79-year-old woman                                                                 Malignant lymphoma                                              Polymorphic ventricular tachycardia.       Thirty minutes into the initial infusion of rituximab               A history of atrial flutter post atrioventricular nodal ablation 1 year before, followed by placement of a pacemaker with 100% ventricular-paced   No ischemic changes, atrial fibrillation with VVIR pacing. The QT interval was technically prolonged.\   NR                                                                                                                                                                    NR                                                                                                                                              Discharged from the hospital a day later\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Interrogation of pacemaker's intracardiac electrogram revealed a 12-second run of polymorphic VT                                                                                                                                                                                                                                                                                                                               No recurrence of arrhythmia at 3-year follow-up

  Lee et al ([@R19])               ‏2012      ‏1                 A 52-year-old woman                                                                 Follicular lymphoma                                             Coronary vasospasm                         Within 10 minutes of first treatment                                No cardiac risk factors other than a seven pack-year smoking history                                                                               New onset T-wave inversion in the anterior precordial leads                                              NR                                                                                                                                                                    Normal cardiac function with no evidence of occlusive disease in the coronary arteries                                                          Rechallenged with rituximab with continuous cardiac monitoring.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      No recurrent chest pain or ECG changes

  Passalia et al ([@R20])          ‏2013      ‏2                 A 75- year-old Caucasian man (case 1) and a 57- year-old Caucasian woman (case 2)   Stage IV non-Hodgkin lymphoma                                   -Case 1: New onset atrial fibrillation\    -Case 1: Immediately after the end of the first infusion\           -Case 1 had a right bundle branch block and several cardiovascular risk factors: cigarette smoking, dyslipidemia, hypertension\                    -Case 1: atrial fibrillation and confirmed RBBB.\                                                        -Case 1: normal LV function with an estimated EF of 50-55%, hypertrophy of the interventricular septum, and mod - erate tricuspid and mitral regurgitation.\          -Case 1: Subsequent coronary arteriography showed multivessel coronary artery disease, for which the patient underwent a stent implantation.\   -Case 1: survived\
                                                                                                                                                                                                                     -Case 2: chest pain                        -Case 2: after the first 90 minutes of infusion                     -Case 2 the patient was a smoker and had previous chemotherapy including high doses of anthracyclines (340 mg cumulative dose).                    -Case 2: sinus tachycardia at a rate of 118 bpm.                                                         -Case 2: did not reveal any pathological alteration                                                                                                                   -Case 2: the patient refused to have further tests                                                                                              -Case 2: recurrence of chest pain occurred when the infusion speed exceeded 50 mL/h with additional cycles.\

  Sellier-Leclerc et al ([@R21])   ‏2013      ‏1                 A 7-year-old boy                                                                    Steroid-dependent idiopathic nephrotic syndrome                 Fulminant viral myocarditis                13 months after the first RTX infusion                              None                                                                                                                                               Non- sustained ventricular tachycardia                                                                   Cardiac dysfunction                                                                                                                                                   NR                                                                                                                                              An endomyocardial biopsy was performed which showed an inflammatory infiltrate, vasculitis and myocardial necrosis; PCR assay of the sample was positive for enterovirus; 2 months later the patient successfully underwent heart transplant surgery.

  Smith et al ([@R22])             ‏2013      1                  A 60-year old woman                                                                 Lymphoma                                                        Takotsubo cardiomyopa-thy                  During infusion of ritux-imab                                       NR; an echocardiogram 3 days before chemo-therapy was normal                                                                                       ST-segment elevation in leads V1 to V6                                                                   Apical ballooning with hyperdynamic basal segments with an EF of 20-25%                                                                                               NR                                                                                                                                              Rituximab was discon-tinued. Discharged home with an angioten-sin-converting enzyme inhibitor and beta-blocker. LVEF was im-proved to 42% at 1 month.

  van Sijl et al‏([@R23])          ‏2014      2                  70-year old (Case 1) and 76-year old women (Case 2)                                 Rheumatoid arthritis                                            Myocardial Infarction                      -Case 1: Three months after first treatment\                        -Case 1: known infero-posterior myocardial infarction post percuta-neous coronary interven-tion.\                                                  -Case 1: ST-elevations suggestive of an anter-olateral myocardial in-farction\                           NR                                                                                                                                                                    -Case 1: a thrombus in the LAD for which a stent was placed\                                                                                    -Case 1: One year later, 2 weeks after the second rituximab administration, patient developed cardi-ac arrest. Repeated cor-onary angiogram showed re-stenosis of several coronaries.\
                                                                                                                                                                                                                                                                -Case 2: One month af-ter the second admin-istration of rituximab   -Case 2: hypertension, hypercholesterolemia, diabetes mellitus or es-tablished coronary heart disease.                                             -Case 2: non-ST elevat-ed myocardial infarction                                                                                                                                                                                                                                -Case 2: functional oc-clusion in the diagonal branch of the left anterior descending                                                           -Case 2: Had conserva-tive treatment, was dis-charged and doing well at 6-month follow-up.

  Mulay et al ([@R35])             ‏2015      1                  A 69-year-old man                                                                   Chronic lymphocytic leukemia                                    Non-ischemic cardiomy-opathy               During the second and third cycles                                  History of inferior wall myocardial infarction, hypertension and hyper-lipidemia                                                                   NR                                                                                                       Dilated LV and severely reduced LV function with EF of 20% after the sec-ond cycle and 10% after his third cycle. There were no regional wall motion abnormalities.   No significant athero-sclerotic disease noted in the coronary vessel.                                                                           The patient received medical treatment for the cardiomyopathy, and required an implantable cardioverter defibrillator for the treatment of symptomatic bradycar-dia.

  Ng et al ([@R24])                ‏2015      1                  A 66-year-old man                                                                   Chronic lymphocytic leukaemia                                   Takotsubo cardiomyopa-thy                  Within 40 min of the in-fusion                                      No previous cardiac his-tory.                                                                                                                      Sinus tachycardia; ST segment elevation in leads I, II and V4--V6                                        Normal LV size with hypokinesis of the ante-rior wall, mild mitral re-gurgitation, aortic regur-gitation and pericardial effusion, but no signs of tamponade.         Non-obstructive distal atheroma with no indica-tion for percutaneous intervention.                                                              Reported no recurrence of his symptoms at fol-low-up.

  Cheungpasitporn et al\           ‏2016      1                  A 51-year-old man                                                                   Membranous nephropathy                                          Non-ischemic cardiomyopathy                Forty-eight hours after the infusion                                No previous cardiac history                                                                                                                        New LBBB                                                                                                 Moderately reduced LV systolic function with an EF of 30% with moderate hypokinesis of anteroseptal myocardium.                                                       No significant athero-sclerotic disease noted in the coronary vessels. There was moderate diffuse hypokinesis of LV on ventriculogram.          At 9 month follow-up, despite that he had bet-ter optimization of his medical therapy, his transthoracic echocardi-ogram still showed re-duced LV EF of 31%.
  (Our case presentation)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  -------------------------------- ---------- ------------------ ----------------------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------ ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Summary of cardiovascular adverse effects related to rituximab treatment

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Cardiovascular adverse effects related to rituximab treatment**
  Hypotension
  Cardiogenic shock
  ACS (angina, unstable angina and myocardial infarction)
  Arrhythmia (monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, supraventricular tachycardia, trigeminy, bradycardia, atrial fibrillation and nonspecific dysrhythmias or tachycardia)
  Reduction in LVEF (may occur within the first few hours after the initial infusion dose or after subsequent doses)
  Non-ischemic Cardiomyopathy
  Takotsubo's cardiomyopathy
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Interestingly, in a randomized controlled trial of single-dose rituximab as induction in renal transplantation, Tydén et al ([@R27]) reported a statistically significant increase in mortality in the rituximab group at 3-year follow-up and 75% of deaths in rituximab-treated recipients were from cardiovascular causes. In a report of 120 patients with follicular and mantle-cell lymphoma treated with rituximab ([@R28]), cardiovascular death was reported in 3 of 4 deaths within 12 months. According to the analysis of mortality associated with rituximab use in autoimmune diseases between 2000 and 2013, fatal outcomes were found in 14 patients out of 134 patients (10.4%). While the majority of patients died from infections, 8% died after cardiac events ([@R29]). These findings in addition to reported cases of ACS/myocardial infarction associated with the infusion of rituximab ([Table 1](#T1){ref-type="table"}) raise the concern of its cardiac side effect profile from rituximab since B-lymphocytes, particularly B1a-lymphocytes, were recently found to provide an atheroprotective effect ([@R30]). Besides, ACS due to coronary vasospasm following rituximab infusion was also reported ([@R19]).

Cardiovascular toxicity in the form of cardiac arrhythmias has been reported in 8% of patients treated with rituximab ([@R2]). These include monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, supraventricular tachycardia, trigeminy, bradycardia, atrial fibrillation and nonspecific dysrhythmias or tachycardia ([@R2],[@R18],[@R31]-[@R35]). It is postulated that the CD 20 antigen also may affect the calcium ion channel ([@R18]). The therapeutic action of rituximab may act by cell lysis via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis. The CD20 antigen is present on immune-effector cells and, after cytotoxic-mediated lysis; it could sequester itself in normal tissues of the body, including cardiac myocytes. It is possible that rituximab affects conduction by inhibiting the calcium-ion-channel properties of the CD20 antigen. Inhibition of calcium-ion channels in cardiac myocytes could lead to the formation of early after-depolarization ([@R18]).

Kanamori et al ([@R16]) reported delayed effect (\>2 weeks following rituximab infusion) of reduced LVEF in 3 cases with NHL ([Table 1](#T1){ref-type="table"}). The prognosis was different in each reported case. Of 3 patients, one had irreversible cardiomyopathy and died with severe heart failure. Partially reversible cardiomyopathy was also recently observed in a case of CLL with cardiomyopathy during treatment with rituximab ([@R24]). In contrast to these reported cases, our case presentation provided very important evidence that rituximab can affect cardiac function. Firstly, in previously reported cases of rituximab induced non-ischemic cardiomyopathy; other concurrent chemotherapeutic agents in addition to rituximab were also given. Thus, it was not conclusive that rituximab was the causative agent. In our case presentation, the patient received only rituximab as a single agent for treatment. Secondly, our case had a coronary angiogram which demonstrated clean coronary artery. Thus, we could confirm the diagnosis of non-ischemic cardiomyopathy, unlike previously reported cases ([@R16]). Thirdly, our case study showed the new finding that a reduction in cardiac function can occur early within 48 hours. Lastly, this case presentation highlights an importance for obtaining family history prior to rituximab treatment. Our patient's family history is remarkable for DCM in his brother. Since familial DCM may occur in 20% to 50% of idiopathic DCM cases ([@R36]), the patient may have had an occult cardiomyopathy that was symptomatically induced by rituximab infusion.

Although the pathophysiology of rituximab induced non-ischemic cardiomyopathy remains unclear, the finding from Kanamori et al ([@R16]) raised an important observation. After rituximab infusion, patients' cardiac myocytes were noted to have diffuse amounts of reticulin ﬁber along with increased serum transforming growth factor-β levels. The investigators suggested that the transforming growth factor-β levels could have led to increased reticulin ﬁber formation causing a decrease in myocardial contractility leading to non-ischemic cardiomyopathy ([@R16]). Also, Takotsubo cardiomyopathy (stress cardiomyopathy), an important type of non-ischemic cardiomyopathy has recently been reported after rituximab infusion ([Table 1](#T1){ref-type="table"}). In our case presentation, the patient had diffuse hypokinesis which was not a typical finding in Takotsubo cardiomyopathy ([@R37]). In addition, most patients with Takotsubo cardiomyopathy recover, unlike our case presentation; LVEF was still significantly reduced at 9-month follow-up.

Conclusion {#s4}
==========

In summary, awareness of cardiotoxicity profile of rituximab is important to minimize the risk of treatment-related morbidity/mortality. In addition to ACS and cardiac arrhythmia, non-ischemic cardiomyopathy can be associated with the infusion of rituximab. This condition may occur early within 48 hours. The occurrence of symptoms that could be ascribed to an ACS or heart failure with reduced ejection fraction (HFrEF) should always be taken seriously during the rituximab infusion and carefully investigated. Patients should be aware that this is a rare, albeit serious, complication of treatment with rituximab. Pretreatment echocardiogram may be helpful when considering rituximab treatment in patients who have a family history of cardiomyopathy.
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